Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 351 to 400 of 797

TitleReference numberPublishedLast updated
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinomaTA666
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpuraTA667
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA663
Liraglutide for managing overweight and obesityTA664
Upadacitinib for treating severe rheumatoid arthritisTA665
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerTA660
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Drug-eluting stents for the treatment of coronary artery diseaseTA152
Guidance on the use of coronary artery stentsTA71
Siponimod for treating secondary progressive multiple sclerosisTA656
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Galcanezumab for preventing migraineTA659
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA648
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Avelumab with axitinib for untreated advanced renal cell carcinomaTA645
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Entrectinib for treating NTRK fusion-positive solid tumoursTA644
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Ustekinumab for treating moderately to severely active ulcerative colitisTA633
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancerTA632
Larotrectinib for treating NTRK fusion-positive solid tumoursTA630
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximabTA629
Lenalidomide with rituximab for previously treated follicular lymphomaTA627
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)TA625
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisTA624
Patiromer for treating hyperkalaemiaTA623

Results per page

  1. 10
  2. 25
  3. 50
  4. All